Hologic, Inc. (HOLX)
After hours:
| Previous close | 76.99 |
| Open | 76.35 |
| Bid | 76.50 x 1100 |
| Ask | 77.90 x 800 |
| Day's range | 75.58 - 77.27 |
| 52-week range | 59.78 - 80.49 |
| Volume | |
| Avg. volume | 1,665,425 |
| Market cap | 18.806B |
| Beta (5Y monthly) | 1.01 |
| PE ratio (TTM) | 15.12 |
| EPS (TTM) | 5.06 |
| Earnings date | 31 Jan 2023 - 06 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 78.33 |
- Business Wire
Hologic Ranked #1 for Mammography System Performance and Customer Satisfaction for 10th Consecutive Year
MARLBOROUGH, Mass., December 01, 2022--Hologic Ranked #1 for Mammography System Performance and Customer Satisfaction for 10th Consecutive Year
- Zacks
Is Trending Stock Hologic, Inc. (HOLX) a Buy Now?
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
- Business Wire
Hologic to Showcase Portfolio of Comprehensive Breast and Skeletal Health Solutions at RSNA 2022
MARLBOROUGH, Mass., November 25, 2022--Hologic, Inc. (Nasdaq: HOLX) will exhibit its extensive portfolio of breast and skeletal health products at the 108th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) from Nov. 27 to Dec. 1. Among the full suite of breast biopsy and surgery solutions will be Hologic’s Affirm® Contrast Biopsy software, which will be on display for the first time since becoming commercially available in the United States.
